ImmuCell posts preliminary Q3 2025 sales update

ImmuCell Corporation filed a current report to let investors know it has released preliminary, unaudited product sales figures for the quarter ended September 30, 2025.

Rhea-AI Filing Summary

ImmuCell Corporation filed a current report to let investors know it has released preliminary, unaudited product sales figures for the quarter ended September 30, 2025. The company communicated these early sales results through a press release dated October 7, 2025, which is included as Exhibit 99.1 to the report. The exhibit is designated as “furnished” rather than “filed,” meaning it is provided for information purposes under securities rules without being incorporated into other filings unless specifically referenced.

Insights

Equity research analyst

Routine 8-K furnishing an early sales update via press release.

ImmuCell Corporation is furnishing an 8-K that points to a press release with preliminary, unaudited product sales for the quarter ended September 30, 2025. Using an 8-K under the results-of-operations item is a standard way to share key topline metrics outside of full quarterly reports.

The company classifies the press release as furnished, not filed, which limits its exposure to certain Exchange Act liabilities while still making the information broadly available. Without the actual sales figures in this excerpt, the business impact of the update cannot be evaluated from this text alone.

Subsequent periodic reports for the quarter ended September 30, 2025 will typically provide complete financial statements and additional context around product sales, margins, and profitability that investors can use to assess performance.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ImmuCell Corporation (ICCC) disclose in this 8-K?

ImmuCell Corporation disclosed that it issued a press release announcing its preliminary, unaudited product sales for the quarter ended September 30, 2025, and furnished that release as an exhibit.

Which period do the preliminary product sales for ImmuCell (ICCC) cover?

The preliminary, unaudited product sales disclosed by ImmuCell Corporation relate to the quarter ended September 30, 2025.

How did ImmuCell (ICCC) provide its preliminary sales information?

ImmuCell Corporation provided its preliminary product sales information through a press release dated October 7, 2025, which is attached as Exhibit 99.1 to the report.

Is ImmuCell’s preliminary sales press release considered filed with the SEC?

The company states that the press release is deemed to be furnished, not filed, under the securities laws, unless specifically incorporated by reference into another filing.

What exhibits are included with this ImmuCell (ICCC) 8-K?

The report includes Exhibit 99.1, the press release dated October 7, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Which SEC item does ImmuCell (ICCC) use for this disclosure?

ImmuCell Corporation uses Item 2.02, Results of Operations and Financial Condition, to present this preliminary product sales disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/07/2025 - 04:06 PM Learn about SEC filing dates

false 0000811641 0000811641 2025-10-07 2025-10-07

FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 7, 2025

ImmuCell Corporation

(Exact name of registrant as specified in its charter)

Delaware		001-12934		01-0382980
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

56 Evergreen Drive Portland, Maine		04103
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code 207-878-2770

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, $0.10 par value per share		ICCC		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.  Results of Operations and Financial Condition

On October 7, 2025 ImmuCell Corporation (the "Company") issued a press release announcing its preliminary, unaudited product sales for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1	Press Release of the Company dated October 7, 2025.
104	Cover page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMMUCELL CORPORATION
Date: October 7, 2025	By:	/s/ Michael F. Brigham
		Michael F. Brigham
		President, Chief Executive Officer and Principal Financial Officer
Date: October 7, 2025	By:	/s/ Timothy C. Fiori
		Timothy C. Fiori
		Chief Financial Officer

2

Exhibit Index

Exhibit No.		Description
99.1		Press Release of the Company dated October 7, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

3